Valneva initiates second Phase II study for its Lyme Disease vaccine candidate
Valneva has announced the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15
Valneva reports successful outcome of Phase 2 run-in for its Lyme disease vaccine candidate
Valneva SE has announced progress of its ongoing Phase 2 study for its leading, unique Lyme disease vaccine candidate, VLA15, into the main study phase
New data further validates Breast Cancer Index ability to predict extended endocrine therapy benefit
Biotheranostics, Inc. announces new pivotal data on the Breast Cancer Index that further validates its ability to accurately predict which women with early-stage, hormone receptor positive breast cancer will benefit from extended endocrine therapy
Valneva reports further positive results for its Chikungunya Vaccine Candidate
Phase I unblinded results up to month 7 showed an excellent immunogenicity and safety profile confirming Valneva's unique, single-shot vaccine candidate
Zipline selected as 2019 Red Herring Top 100 North America Winner
ZipLine Medical, Inc. was selected as a winner of the Red Herring Top 100 North America award, which recognizes the continent's most exciting and innovative private technology companies
MVM announces partial sale of its holding in Ambio
MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group
Alliance Pharma acquires Nizoral rights in APAC region
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.
Alliance Pharma receives positive opinion for Diclectin
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.
Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.
Clinical study supports the use of Cheetah Medical's technologies
Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock